Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium

Liora Schultz; Elad Jacoby; Adam J. Lamble; Shannon L. Maude; Kevin O. McNerney; Amy Moskop; Regina M. Myers; Michael A. Pulsipher; Nirali N. Shah

doi:10.1016/j.jtct.2023.07.009

Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium

Liora Schultz^*, Elad Jacoby, Adam J. Lamble, Shannon L. Maude, Kevin O. McNerney, Amy Moskop, Regina M. Myers, Michael A. Pulsipher, Nirali N. Shah^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	592-593
Number of pages	2
Journal	Transplantation and Cellular Therapy
Volume	29
Issue number	10
DOIs	https://doi.org/10.1016/j.jtct.2023.07.009
State	Published - Oct 2023

Funding

The authors acknowledge the speakers and chairs of the INSPIRED Symposium (https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Conflict of interest statement: L.M.S. reports serving on advisory boards for Novartis and Cargo Therapeutics. E.J. reports receiving honoraria from Novartis. S.L.M reports clinical trial support: Novartis, Wugen; consulting, advisory boards, or study steering committee: Novartis, and patent pending and licensed to Novartis Pharmaceuticals for PCT/US2017/044425: Combination Therapies for Car and PD-1 Inhibitors. M.A.P. reports serving on advisory boards for Cargo Therapeutics, Novartis, Gentibio, Bluebird, Vertex, Medexus, and Equillium; receiving study support from Adaptive and Miltenyi. N.N.S. reports attending advisory board meetings for Sobi and VOR. Authorship statement: N.N.S drafted the first version of this manuscript, however all authors provided substantial edits and input into the concept and manuscript writing. All authors provided final approval of manuscript and all authors are accountable for all aspects of work. Financial disclosure: See Acknowledgments on page 593. Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. The authors acknowledge the speakers and chairs of the INSPIRED Symposium ( https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023 ) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823).

Keywords

Acute lymphoblastic leukemia
Children and young adults
Chimeric antigen receptor T-cells
Immunotherapy
Relapse
Salvage therapy

ASJC Scopus subject areas

Immunology and Allergy
Molecular Medicine
Hematology
Cell Biology
Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jtct.2023.07.009

Cite this

Schultz, L., Jacoby, E., Lamble, A. J., Maude, S. L., McNerney, K. O., Moskop, A., Myers, R. M., Pulsipher, M. A., & Shah, N. N. (2023). Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium. Transplantation and Cellular Therapy, 29(10), 592-593. https://doi.org/10.1016/j.jtct.2023.07.009

@article{6add9723a4b04afaa879bc4c2d1bb60b,

title = "Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium",

keywords = "Acute lymphoblastic leukemia, Children and young adults, Chimeric antigen receptor T-cells, Immunotherapy, Relapse, Salvage therapy",

author = "Liora Schultz and Elad Jacoby and Lamble, \{Adam J.\} and Maude, \{Shannon L.\} and McNerney, \{Kevin O.\} and Amy Moskop and Myers, \{Regina M.\} and Pulsipher, \{Michael A.\} and Shah, \{Nirali N.\}",

note = "Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium (https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Conflict of interest statement: L.M.S. reports serving on advisory boards for Novartis and Cargo Therapeutics. E.J. reports receiving honoraria from Novartis. S.L.M reports clinical trial support: Novartis, Wugen; consulting, advisory boards, or study steering committee: Novartis, and patent pending and licensed to Novartis Pharmaceuticals for PCT/US2017/044425: Combination Therapies for Car and PD-1 Inhibitors. M.A.P. reports serving on advisory boards for Cargo Therapeutics, Novartis, Gentibio, Bluebird, Vertex, Medexus, and Equillium; receiving study support from Adaptive and Miltenyi. N.N.S. reports attending advisory board meetings for Sobi and VOR. Authorship statement: N.N.S drafted the first version of this manuscript, however all authors provided substantial edits and input into the concept and manuscript writing. All authors provided final approval of manuscript and all authors are accountable for all aspects of work. Financial disclosure: See Acknowledgments on page 593. Funding Information: Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium ( https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023 ) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. Funding Information: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). ",

year = "2023",

month = oct,

doi = "10.1016/j.jtct.2023.07.009",

language = "English (US)",

volume = "29",

pages = "592--593",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier B.V.",

number = "10",

}

Schultz, L, Jacoby, E, Lamble, AJ, Maude, SL, McNerney, KO, Moskop, A, Myers, RM, Pulsipher, MA & Shah, NN 2023, 'Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium', Transplantation and Cellular Therapy, vol. 29, no. 10, pp. 592-593. https://doi.org/10.1016/j.jtct.2023.07.009

TY - JOUR

T1 - Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy

T2 - Recent Advances and Future Directions (INSPIRED) Symposium

AU - Schultz, Liora

AU - Jacoby, Elad

AU - Lamble, Adam J.

AU - Maude, Shannon L.

AU - McNerney, Kevin O.

AU - Moskop, Amy

AU - Myers, Regina M.

AU - Pulsipher, Michael A.

AU - Shah, Nirali N.

N1 - Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium (https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Conflict of interest statement: L.M.S. reports serving on advisory boards for Novartis and Cargo Therapeutics. E.J. reports receiving honoraria from Novartis. S.L.M reports clinical trial support: Novartis, Wugen; consulting, advisory boards, or study steering committee: Novartis, and patent pending and licensed to Novartis Pharmaceuticals for PCT/US2017/044425: Combination Therapies for Car and PD-1 Inhibitors. M.A.P. reports serving on advisory boards for Cargo Therapeutics, Novartis, Gentibio, Bluebird, Vertex, Medexus, and Equillium; receiving study support from Adaptive and Miltenyi. N.N.S. reports attending advisory board meetings for Sobi and VOR. Authorship statement: N.N.S drafted the first version of this manuscript, however all authors provided substantial edits and input into the concept and manuscript writing. All authors provided final approval of manuscript and all authors are accountable for all aspects of work. Financial disclosure: See Acknowledgments on page 593. Funding Information: Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium ( https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023 ) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. Funding Information: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823).

PY - 2023/10

Y1 - 2023/10

KW - Acute lymphoblastic leukemia

KW - Children and young adults

KW - Chimeric antigen receptor T-cells

KW - Immunotherapy

KW - Relapse

KW - Salvage therapy

UR - https://www.scopus.com/pages/publications/85167985127

UR - https://www.scopus.com/inward/citedby.url?scp=85167985127&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2023.07.009

DO - 10.1016/j.jtct.2023.07.009

M3 - Comment/debate

C2 - 37442348

AN - SCOPUS:85167985127

SN - 2666-6367

VL - 29

SP - 592

EP - 593

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 10

ER -

Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this